RCT of Different Effects of Nucleot(s)Ide Analogues on the Prognosis of HBV-HCC Patients After Curative Resection

NCT04032860 · clinicaltrials.gov ↗

PHASE4

Phase

ACTIVE_NOT_RECRUITING

Status

104

Enrollment

OTHER

Sponsor class

Conditions

HCC
HBV Coinfection

Interventions

DRUG: Tenofovir Disoproxil
DRUG: Entecavir

Sponsor

West China Hospital